ARTICLES BY MATTHEW PILLAR

• Single Use In Biopharma: Beyond Savings & Sustainability

  4/17/2024

  SUT continues to trend in biopharmaceutical applications, driven largely by environmental and economic considerations. But there’s a lot more to the SUT story, including supply chain and standardization advantages. On April 24 at 11 AM ET, we’re diving into it live with independent SUT expert Paul Priebe and Krystal Biotech VP of Technical Operations Mark Petrich.

• Eying Up The Era Of Topical Biologics

  3/19/2024

  Claris Bio’s phase 1/2 clinical trial in patients with Stage 2 or 3 Neurotrophic Keratitis (NK) is breaking new ground in the development of topically administered biologic therapies. 

• Debra Weiss, RN: Big Impact In Small, Non-Profit Bio

  3/8/2024

  The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.

• Antibody-Drug Conjugates: Increasing Investment In R&D And Partnership

  2/1/2023

  DeciBio’s Antibody-Drug Conjugates 2023 Industry Survey points to progress in ADC development. Respondents anticipate lower regulatory, financial, and R&D barriers as the technology matures. Senior Life Science Expert Joe Daccache, Ph.D. gave us an insider's look at the numbers.

• The Coming Wave Of Radio(bio)pharmaceuticals

  6/13/2022

  Convergent Therapeutics is bullish on the combination of radioisotopes and antibodies to direct radiation directly to cancer cells. As enabling technologies improve on previous failures, CEO, CMO, and co-founder Dr. Philip Kantoff is projecting a new wave of activity in the space among biopharmas big and small.

• Computational Science: Disruption In Biopharma Discovery

  3/12/2021

  NeuBase Therapeutics CEO Dr. Dietrich Stephan discusses the important role computational drug discovery plays as we emerge from what he characterizes as “a decades-long, multi-billion-dollar chemical engineering escapade with a very low success rate to find one drug.”

• Are Dry Powder Biologics Ready For Primetime?

  9/21/2020

  A new approach to freezing biopharmaceuticals into fine, dry powders holds promise for flexible therapeutic form factors, efficacy improvements, and supply and distribution chain efficiencies. It's a particularly timely development in the age of COVID-19.

• The Compounded Risk Of Early-Stage Biopharma Licensing Deals

  6/25/2020

  For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.

• Mechanistic Action: Genesis Of A Biologics Pipeline?

  6/17/2020

  Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.

• Precision Medicine In Practice

  6/16/2020

  Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.

• Securing Biotech Funding When Economies Get Wild

  6/12/2020

  There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times. 

• A New Cost Paradigm For CAR Cell Therapies?

  6/12/2020

  Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.

• Is Biopharma’s Response To Coronavirus Off The Mark?

  3/4/2020

  As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.